文献速递免疫规划卫生政策与健康促进

BNT162b2新冠疫苗减量同源加强针的安全性与免疫原性:单盲随机非劣效随访试验

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.
PubMed 文献 · Vaccine · 2026-07-03

在比利时开展的单盲随机非劣效随访试验纳入132名≥18岁成人,随机接受10 μg或30 μg BNT162b2加强针。减量组反应原性显著更低(41% vs 78%,P<0.0001),但第28天未达体液免疫非劣效标准;至6个月两组抗体差异消失,突破感染率无显著差异。

要点

  • 减量加强针反应原性显著低于全剂量(41% vs 78%,P<0.0001)。
  • 第28天减量组未达体液免疫非劣效标准,但6个月时差异消失。
  • 两组突破感染率(69% vs 62%,P=0.56)及症状学相似。

核心结论

  • 减量加强针短期体液免疫应答略低于全剂量,但6个月时差异消失且对突破感染率无影响。
  • 结合显著更低的反应原性,减量方案可作为维持免疫、减轻公共卫生负担的成本效益策略。

研究设计与样本

  • 单盲、随机、非劣效随访试验,在比利时开展,纳入132名≥18岁健康成人。
  • 参与者来自REDU-VAC队列,先前接种两剂20 μg或30 μg BNT162b2,随机接受10 μg或30 μg加强针。
  • 于基线(D0)、第28天(D28)和第6个月(M6)采集血样,主要结局为D28时SARS-CoV-2抗RBD IgG几何平均滴度(GMT)。

主要发现

  • 未报告危及生命的不良事件。
  • 减量组反应原性显著更低(41% vs 78%,P<0.0001)。
  • 基线滴度不受初免剂量浓度影响,既往感染者滴度更高。
  • D28时减量加强针未达体液免疫应答非劣效标准。
  • 至M6两组抗体滴度均下降,减量与全剂量受者间无显著差异;突破感染率(69% vs 62%,P=0.56)及症状学可比。

关键数值与推荐

  • 减量剂量为10 μg,全剂量为30 μg BNT162b2加强针。
  • 主要结局非劣效分析在D28进行,减量组未达非劣效标准。
  • 反应原性减量组41% vs 全剂量组78%,P<0.0001。
  • 突破感染率减量组69% vs 全剂量组62%,P=0.56。

临床怎么用

  • 减量加强针可显著降低反应原性,且6个月时免疫差异消失、突破感染率无差异。
  • 在疫苗供应有限或需提高接种接受度时,可考虑减量加强策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reduced-dose primo-vaccination against COVID-19 demonstrated safety and immunogenicity, as evidenced by us and others. Fractional booster dosing may similarly maintain strong immunogenicity and protection while reducing reactogenicity, improving acceptability, and conserving supplies. OBJECTIVE: To evaluate the safety and humoral immunogenicity of a reduced-dose (10 μg) versus full-dose (30 μg) BNT162b2 booster in healthy adults. METHODS: In this single-blind, randomized, non-inferiority follow-up trial in Belgium, 132 adults ≥18 years were enrolled, including participants from the REDU-VAC cohort primed with two doses of either 20 μg or 30 μg BNT162b2. Randomized participants received a 10 μg or 30 μg booster. Blood samples were collected at baseline (D0), day 28 (D28), and month 6 (M6). The primary outcome was SARS-CoV-2 anti-RBD IgG geometric mean titers (GMT) at D28. Secondary outcomes included safety, reactogenicity, anti-RBD IgG titers, neutralizing antibody titers (Wuhan, Omicron BA.1), avidity, and incidence of breakthrough infections (BTI) post D28. Mixed-effects linear models were used to assess the impacts, and a non-inferiority analysis was conducted at D28. RESULTS: No life-threatening adverse events were reported. Reactogenicity was significantly lower in the reduced-dose group (41% vs. 78%, P < 0.0001). Baseline titers were unaffected by priming dose concentration, while previously infected participants exhibited higher titers. At D28, the reduced-dose booster did not meet non-inferiority criteria for humoral immune responses. By M6, antibody titers declined across both groups, with no significant differences between reduced- and full-dose recipients. BTI incidence (69% vs. 62%, P = 0.56) and symptomatology were comparable between groups. CONCLUSIONS: The reduced-dose booster elicited moderately lower short-term humoral responses compared to the full dose, but these differences disappeared by six months and had no detectable impact on BTI rates. Combined with a significantly lower reactogenicity profile, reduced-dose regimens represent a cost-effective strategy to sustain immunity and reduce public health burdens. The study was registered at Clinicaltrials.gov (NCT04852861).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Depickère S, Pannus P, Houben S, et al. Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial. Vaccine. 2026. PMID: 42398210. doi:10.1016/j.vaccine.2026.128897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。